235 related articles for article (PubMed ID: 35784328)
1. MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and Prognosis.
Zhong C; Xie Z; Zeng LH; Yuan C; Duan S
Front Immunol; 2022; 13():855078. PubMed ID: 35784328
[TBL] [Abstract][Full Text] [Related]
2. LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder.
Pei L; Yan D; He Q; Kong J; Yang M; Ruan H; Lin Q; Huang L; Huang J; Lin T; Qin H
Cell Oncol (Dordr); 2023 Oct; 46(5):1509-1527. PubMed ID: 37355516
[TBL] [Abstract][Full Text] [Related]
3. LncRNA MIR4435-2HG-mediated upregulation of TGF-β1 promotes migration and proliferation of nonsmall cell lung cancer cells.
Yang M; He X; Huang X; Wang J; He Y; Wei L
Environ Toxicol; 2020 May; 35(5):582-590. PubMed ID: 31875359
[TBL] [Abstract][Full Text] [Related]
4. MIR4435-2HG: A newly proposed lncRNA in human cancer.
Zhang M; Yu X; Zhang Q; Sun Z; He Y; Guo W
Biomed Pharmacother; 2022 Jun; 150():112971. PubMed ID: 35447550
[TBL] [Abstract][Full Text] [Related]
5. LncRNA MIR4435-2HG contributes into colorectal cancer development and predicts poor prognosis.
Shen MY; Zhou GR; -Y Zhang Z
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1771-1777. PubMed ID: 32141545
[TBL] [Abstract][Full Text] [Related]
6. lncRNA MIR4435-2HG Accelerates the Development of Bladder Cancer through Enhancing IQGAP3 and CDCA5 Expression.
Yang T; Li Y; Wang G; Guo L; Sun F; Li S; Deng X; Liu J
Biomed Res Int; 2022; 2022():3858249. PubMed ID: 35993042
[TBL] [Abstract][Full Text] [Related]
7. MIR4435-2HG: A Tumor-associated Long Non-coding RNA.
Zhao F; Liu Y; Tan F; Tang L; Du Z; Mou J; Zhou G; Yuan C
Curr Pharm Des; 2022; 28(25):2043-2051. PubMed ID: 35674305
[TBL] [Abstract][Full Text] [Related]
8. The lncRNA MIR4435-2HG promotes lung cancer progression by activating β-catenin signalling.
Qian H; Chen L; Huang J; Wang X; Ma S; Cui F; Luo L; Ling L; Luo K; Zheng G
J Mol Med (Berl); 2018 Aug; 96(8):753-764. PubMed ID: 29872866
[TBL] [Abstract][Full Text] [Related]
9. LncRNA MIR4435-2HG targets desmoplakin and promotes growth and metastasis of gastric cancer by activating Wnt/β-catenin signaling.
Wang H; Wu M; Lu Y; He K; Cai X; Yu X; Lu J; Teng L
Aging (Albany NY); 2019 Sep; 11(17):6657-6673. PubMed ID: 31484163
[TBL] [Abstract][Full Text] [Related]
10. LncRNA MIR4435-2HG functions as a ceRNA against miR-125a-5p and promotes neuroglioma development by upregulating TAZ.
Shen W; Zhang J; Pan Y; Jin Y
J Clin Lab Anal; 2021 Dec; 35(12):e24066. PubMed ID: 34714963
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA MIR4435-2HG: a key molecule in progression of cancer and non-cancerous disorders.
Ghasemian M; Rajabibazl M; Sahebi U; Sadeghi S; Maleki R; Hashemnia V; Mirfakhraie R
Cancer Cell Int; 2022 Jun; 22(1):215. PubMed ID: 35715800
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of long non-coding RNA MR4435-2HG suppresses breast cancer progression via the Wnt/β-catenin signaling pathway.
Chen D; Tang P; Wang Y; Wan F; Long J; Zhou J; Zhuang M; Chen X
Oncol Lett; 2021 May; 21(5):373. PubMed ID: 33777197
[TBL] [Abstract][Full Text] [Related]
13. N6-methyladenosine-modified oncofetal lncRNA MIR4435-2HG contributed to stemness features of hepatocellular carcinoma cells by regulating rRNA 2'-O methylation.
Zhu Y; Xiao B; Liu M; Chen M; Xia N; Guo H; Huang J; Liu Z; Wang F
Cell Mol Biol Lett; 2023 Oct; 28(1):89. PubMed ID: 37891494
[TBL] [Abstract][Full Text] [Related]
14. LncRNA MIR4435-2HG is a potential early diagnostic marker for ovarian carcinoma.
Gong J; Xu X; Zhang X; Zhou Y
Acta Biochim Biophys Sin (Shanghai); 2019 Sep; 51(9):953-959. PubMed ID: 31435668
[TBL] [Abstract][Full Text] [Related]
15. Long Noncoding RNA MIR4435-2HG Suppresses Colorectal Cancer Initiation and Progression By Reprogramming Neutrophils.
Yu H; Chen C; Han F; Tang J; Deng M; Niu Y; Lai M; Zhang H
Cancer Immunol Res; 2022 Sep; 10(9):1095-1110. PubMed ID: 35862232
[TBL] [Abstract][Full Text] [Related]
16. LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1.
Luo P; Wu S; Ji K; Yuan X; Li H; Chen J; Tian Y; Qiu Y; Zhong X
PLoS One; 2020; 15(11):e0223035. PubMed ID: 33232319
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA MIR4435-2HG recruits miR-802 from FLOT2 to promote melanoma progression.
Ma DM; Sun D; Wang J; Jin DH; Li Y; Han YE
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2616-2624. PubMed ID: 32196611
[TBL] [Abstract][Full Text] [Related]
18. LncRNA MIR4435-2HG potentiates the proliferation and invasion of glioblastoma cells via modulating miR-1224-5p/TGFBR2 axis.
Xu H; Zhang B; Yang Y; Li Z; Zhao P; Wu W; Zhang H; Mao J
J Cell Mol Med; 2020 Jun; 24(11):6362-6372. PubMed ID: 32319715
[TBL] [Abstract][Full Text] [Related]
19. Hepatic stellate cell-released CXCL1 aggravates HCC malignant behaviors through the MIR4435-2HG/miR-506-3p/TGFB1 axis.
Li S; Hu X; Yu S; Yi P; Chen R; Huang Z; Huang Y; Huang Y; Zhou R; Fan X
Cancer Sci; 2023 Feb; 114(2):504-520. PubMed ID: 36169092
[TBL] [Abstract][Full Text] [Related]
20. The lncRNA MIR4435-2HG is upregulated in hepatocellular carcinoma and promotes cancer cell proliferation by upregulating miRNA-487a.
Kong Q; Liang C; Jin Y; Pan Y; Tong D; Kong Q; Zhou J
Cell Mol Biol Lett; 2019; 24():26. PubMed ID: 30988676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]